ACE and chronic kidney disease: ACE inhibitors and ARB have been shown to have a renoprotective effect and reduced morbidity and mortality in patients with chronic kidney disease [22,23] However, the strategy of dual RAAS inhibition seems to have different clinical impacts in diabetic and non-diabetic CKD patients.